Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504836 | 1.00 | DRD4 (0.60) | DRD4CYP1A2CYP2C9CYP2C19CCR3 | |
| SCHEMBL8327760 | 0.90 | DRD4 (0.60) | DRD4CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1502135 | 0.88 | DRD4 (0.60) | DRD4CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL2768626 | 0.88 | DRD4 (0.60) | DRD4CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL2768622 | 0.88 | DRD4 (0.60) | DRD4CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL6230220 | 0.86 | DRD4 (0.61) | DRD4CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL6665171 | 0.85 | DRD4 (0.57) | DRD4CYP1A2CYP2C9CCR3CYP3A4 | |
| SCHEMBL4031677 | 0.77 | DRD4 (0.65) | DRD4CYP1A2CYP2C9CCR3CYP3A4 | |
| SCHEMBL1809499 | 0.77 | DRD4 (0.65) | DRD4CYP1A2CYP2C9CCR3CYP3A4 | |
| SCHEMBL4026839 | 0.77 | DRD4 (0.65) | DRD4CYP1A2CYP2C9CCR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7560548-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-7101882-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | disclosed |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ANCLIFF RACHAEL A | 2006-04-13 | — | — | US | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1586567-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1324991-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026723-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | DRD4 3922/4885CYP1A2 149/4885CYP2C9 658/4885 |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ARG1, ARG2, NFKBIA | DRD4 2049/4885CYP1A2 67/4885CYP2C9 1666/4885 |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | TNF, IL1B, IL4 | DRD4 1474/4885CYP1A2 319/4885CYP2C9 1531/4885 |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ARG1, ARG2, NFKBIA | DRD4 2049/4885CYP1A2 67/4885CYP2C9 1666/4885 |
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | DRD4 1757/4885CYP1A2 2390/4885CYP2C9 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.